Abstract:
A wind farm installation vessel (1) at open see at the area of the off-shore installation site is ballasted to a first draught, at which the cargo main deck (5) is submerged below sea level, and at least two jack-up legs (2) on the wind farm installation vessel are brought into contact with the sea bottom (10), and a barge (11) with parts for construction of the wind farm is received at a cargo main deck of the vessel, following which the vessel (1) is positioned at a particular site of installation and is jacked-up by at least four jack-up legs (2) on the vessel, and a main crane or other lifting equipment on the vessel lifts a part from the barge (11) on the main cargo deck to the wind turbine construction erected from the sea bottom.
Abstract:
There are provided novel compounds of formula (I), wherein R 1 , R 2 , R 4 , R 5 , G 1 , G 2 , L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
Abstract:
A plasma deposition apparatus for making high purity silicon, including a chamber for depositing said high purity silicon, the chamber including a top defining substantially an upper end of die chamber; one or more sides having an upper end and a lower end, the top substantially sealingly joining the upper end of the one or more sides; a base defining substantially a lower end of the chamber, the base substantially sealingly joining the lower end of the one or more sides; and at least one induction coupled plasma torch disposed in the top, the at least one induction coupled plasma torch oriented in a substantially vertical position producing a plasma flame downward from the top towards the base, the plasma flame defining a reaction zone for reacting one or more reactants to produce the high purity silicon. In addition, methods for collecting molten silicon are also provided.
Abstract:
The present invention provides compounds of formula (I) wherein n, p, R 1 , R 2 , X 1 , X 2 , X 3 , X 4 , X 5 , R 3a , R 3b , R 4 , R 5 and R 6 are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
Abstract:
The invention provides compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 and X are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
Abstract:
In a trading environment that comprises buy side traders and securities brokers, a computer process capable of preventing securities brokers from receiving information irrelevant to a commission payment for a securities transaction. The process comprises means for providing an overview of commission payments for a predetermined time period, means for providing details of step-out payments for the predetermined period, means for adjusting step-in amounts and frequencies, means for providing notification that a commission payment has been stepped out and is capable of being credited, means for automatically suggesting and performing step-ins and step-outs, and means for assessing the step-outs and step-ins against a predetermined budget.
Abstract:
The invention provides compounds of formula (I) wherein R 1 , R 3 , R 4 , R 5 , R 14 , X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
Abstract translation:本发明提供式(I)化合物,其中R 1,R 3,R 4,R 5, R 14,X和W如说明书和光学异构体,外消旋体和互变异构体及其药学上可接受的盐所定义; 以及其制备方法,含有它们的药物组合物及其在治疗中的用途。 这些化合物是人嗜中性粒细胞弹性蛋白酶的抑制剂。
Abstract:
The present invention relates to novel azaindole compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them.
Abstract:
Bei einer Beutelverpackung mit aus wenigstens einer flexiblen Verpackungsfolie gebildeter Beutelfrontwand (12) und Beutelruckwand (14) zum Verpacken von fliessfähigem Füllgut (11) sind die Beutelfrontwand (12) und die Beutelrückwand (14) über eine Siegelnaht (24) miteinander verbunden. Die Siegelnaht (24) ist in einem an einen Siegelrand (16) angrenzenden Bereich zu einer vom Siegelrand (16) weg gerichteten Siegelzone (26) mit einem vom Siegelrand (16) am weitesten entfernten freien Ende (27) erweitert. Die Beutelfrontwand (12) weist auf der gegen die Aussenseite der Beutelverpackung gerichteten Seite eine Aussenschicht (28) auf. Die Aussenschicht (28) und der unter der Aussenschicht (28) liegenden Teil (29) der Beutelfrontwand (12) begrenzen in einem das freie Ende (27) der Siegelzone (26) einschliessenden, sich bis zu einer Randkante (17) des Siegelrandes (16) erstreckenden Flächenbereich?eine Auslaufzone (30) für das Füllgut (11). Bei Druckbeaufschlagung bildet sich in dem unter der Aussenschicht (28) liegenden Teil (29) der Beutelfrontwand (12) im Bereich des freien Endes (27) der Siegelzone (26) ein Riss (38) und das Füllgut (11) tritt in die Auslaufzone (30) ein und an der Randkante (17) des Siegelrandes (16) aus der Beutelverpackung aus.
Abstract:
A computer system provides for changing the power states of data-handling devices in response to a detection of a change in the redundancy associated with energy-transfer devices.